1/104
Looks like no tags are added yet.
IDA - key investigations
CBC: low Hb, MCV < 80, MCH/MCHC low, RDW high; film: microcytic hypochromic, pencil cells; retics low/normal; serum iron low, TIBC high, ferritin low (< 13 ug/L), transferrin saturation low; find the source (stool occult blood, endoscopy)
IDA - best diagnostic test
Serum ferritin (most sensitive and specific); in inflammation ferritin < 30 suggests IDA, > 100 makes it unlikely
IDA - treatment
Treat the cause; oral ferrous sulfate 325 mg TDS (65 mg elemental iron) on an empty stomach with vitamin C for 3-6 months after Hb normalizes; IV iron (ferric carboxymaltose) if oral fails or not tolerated; transfusion only if Hb < 7 with compromise
IDA - important points
Most common anemia worldwide; koilonychia, pica, glossitis, angular stomatitis; Plummer-Vinson = web + dysphagia + IDA; Hb rises 1-2 g/dL every 2-3 weeks; retics peak at 7-10 days; Ganzoni formula for IV iron dose
Beta-thalassemia major - investigations
Hb 2-6, MCV 50-65, RDW normal; film: target cells, nucleated RBCs, tear drops; HPLC: HbF 60-90%, HbA2 high, little/no HbA; ferritin high; skull X-ray hair-on-end; MRI T2* of heart and liver
Beta-thalassemia major - treatment
Regular leukocyte-depleted transfusions every 3-4 weeks; folic acid 5 mg/day; iron chelation (deferoxamine, deferasirox, deferiprone); splenectomy for hypersplenism; curative: allogeneic SCT
Beta-thalassemia major - important points
Presents at 3-6 months when HbF falls; thalassemic facies; leading cause of death is iron-overload cardiomyopathy; start chelation at ferritin > 1000 or after 10-15 transfusions; MRI T2* is the gold standard for iron quantification
Beta-thalassemia minor - diagnosis and treatment
Mild anemia, low MCV, normal RDW, HbA2 > 3.5% (diagnostic), normal ferritin; no treatment needed; genetic counseling
Beta-thal minor vs IDA - important points
Beta-thal minor: RBC count HIGH, RDW normal, HbA2 > 3.5%, ferritin normal; IDA: RBC count low, RDW high, ferritin low
Alpha-thalassemia - diagnosis and treatment
HbH disease: Hb 7-11, retics 5-10%, brilliant cresyl blue shows golf-ball inclusions, HbH on HPLC; treat with intermittent transfusions, folic acid, chelation, splenectomy; Hb Barts hydrops: HPLC Hb Barts 70-90%, absent HbF, incompatible with life
Alpha-thalassemia - important points
4 alpha genes on chromosome 16; 1 deletion = silent carrier; 2 = trait; 3 = HbH disease; 4 = Hb Barts hydrops fetalis
Sideroblastic anemia/lead toxicity - diagnosis and treatment
Ringed sideroblasts (Prussian blue), basophilic stippling, HIGH iron and ferritin; remove lead source and give chelation; never give iron
Hemolysis - general diagnosis
Increased retics, indirect bilirubin, LDH; low haptoglobin; blood film for morphology; DAT (Coombs) to look for immune cause
Intravascular vs extravascular hemolysis - key differences
Intravascular: marked low haptoglobin, free plasma Hb, hemoglobinuria, marked LDH rise (e.g., G6PD, PNH, TTP); extravascular: normal/slightly low haptoglobin, no hemoglobinuria, mild LDH rise (e.g., HS, AIHA)
Hereditary spherocytosis - diagnosis and treatment
Normocytic anemia, spherocytes, extravascular hemolysis markers; osmotic fragility (increased) or EMA binding test; treat with folic acid and splenectomy (vaccinate first against pneumococcus, meningococcus, Hib)
Hereditary spherocytosis - important points
Autosomal dominant (75%); spectrin/ankyrin defect; complications: gallstones, aplastic crisis (parvovirus B19), megaloblastic crisis (folate)
G6PD deficiency - diagnosis and treatment
Film: Heinz bodies, bite and blister cells; G6PD enzyme assay AFTER the acute episode; supportive treatment: remove trigger, hydration, transfuse if severe
G6PD deficiency - important points
X-linked recessive; triggers: infections (most common), primaquine, dapsone, nitrofurantoin, rasburicase, sulfas, fava beans; mainly intravascular hemolysis; neonatal jaundice
Sickle cell disease - diagnosis
Hb electrophoresis is the gold standard (HbSS: HbS 80-95%, no HbA); HPLC for newborn screening; sickle solubility test is screening only; film: sickle cells, target cells, Howell-Jolly bodies
Sickle cell disease - long-term treatment
Vaccines (pneumococcal, Hib, meningococcal, hepatitis B); penicillin prophylaxis until at least age 5; folic acid 5 mg/day; hydroxyurea (raises HbF); transfusion for complications; curative: allogeneic SCT
Sickle cell disease - acute pain crisis treatment
Treat precipitants, analgesia by WHO ladder up to IV morphine, IV hydration (careful), oxygen if SpO2 < 95%, incentive spirometry
Sickle cell disease - important points
Glu to Val at beta-6; HbF inhibits sickling; dactylitis in infants; acute chest syndrome is the leading cause of death in adults; autosplenectomy by age 5; transcranial Doppler yearly in children 2-16
Hydroxyurea - important points
Raises HbF, lowers neutrophils; indicated for >= 3 crises/year, ACS, severe anemia; reduces crises by ~50%; side effects: myelosuppression and teratogenicity
Warm AIHA - diagnosis and treatment
IgG, DAT positive (IgG +/- C3d), spherocytes; prednisolone 1 mg/kg/day, then IVIG, rituximab, splenectomy
Cold AIHA - diagnosis and treatment
IgM, DAT positive for C3d only, agglutination on film; avoid cold, treat cause (Mycoplasma, EBV, lymphoma), rituximab; steroids usually ineffective
Direct vs indirect Coombs - important points
Direct: antibodies/complement on patient's RBCs (AIHA, transfusion reaction, HDN); indirect: patient's serum antibodies against donor RBCs (cross-matching)
MAHA/TTP - diagnosis
Schistocytes > 1% = MAHA until proven otherwise (emergency); TTP: severe thrombocytopenia, low ADAMTS13 activity (< 10%), normal PT/PTT and fibrinogen
TTP - treatment
Urgent plasma exchange; steroids and rituximab for acquired TTP; untreated TTP is 90% fatal
TTP vs DIC - important points
TTP: ADAMTS13 deficiency, normal PT/PTT/fibrinogen, plasma exchange; DIC: tissue factor activation, prolonged PT/PTT, low fibrinogen, treat the cause
Aplastic anemia - investigations
Pancytopenia, retics < 20 x 10^9/L, hypocellular marrow < 25% with fat replacement, no fibrosis or infiltration; normal karyotype; flow cytometry CD55/CD59 for PNH clone; viral serology; Fanconi screen (chromosomal breakage); HLA typing
Aplastic anemia - treatment
Supportive: transfuse (Hb > 8, platelets > 10) with irradiated CMV-negative products, infection prophylaxis; definitive: allogeneic SCT if < 40 with matched sibling; otherwise ATG + cyclosporine +/- eltrombopag
Aplastic anemia - important points
Immune-mediated (T cells, IFN-gamma, TNF-alpha); idiopathic 70%; chloramphenicol, benzene; no lymphadenopathy or splenomegaly (if present think leukemia/lymphoma); severe = marrow < 25% + 2 of 3 (neutrophils < 0.5, platelets < 20, retics < 20)
PNH - diagnosis and important points
Flow cytometry for CD55 and CD59; PIG-A mutation (no GPI anchor); chronic intravascular hemolysis, thrombosis (leading cause of death; Budd-Chiari), marrow failure; urinary iron loss causes iron deficiency
Anemia of chronic disease - diagnosis
Normal/low MCV, low iron, low/normal TIBC, normal/HIGH ferritin, HIGH hepcidin, normal sTfR, raised ESR/CRP; Hb usually 8-10
Anemia of chronic disease - treatment
Treat the underlying disease; ESAs in CKD or chemotherapy (target Hb 10-12); IV iron if coexistent IDA; transfusion if Hb < 7-8 and symptomatic; oral iron is not helpful
Anemia of chronic disease - important points
Second most common anemia; IL-6 raises hepcidin, which degrades ferroportin and traps iron; sTfR/log ferritin > 2 suggests coexistent IDA
Megaloblastic anemia - investigations
MCV > 100; hypersegmented neutrophils (pathognomonic) and macro-ovalocytes; low retics; low B12 (< 200 pg/mL); RBC folate; MMA high ONLY in B12 deficiency; homocysteine high in both; high LDH; anti-parietal cell and anti-intrinsic factor antibodies
Megaloblastic anemia - treatment
B12: IM hydroxocobalamin 1000 ug daily x 7 days, weekly x 4, then every 3 months for life; folate: folic acid 5 mg daily for 4 months; NEVER give folate alone before treating B12 deficiency
Megaloblastic anemia - important points
Pernicious anemia is the most common cause of B12 deficiency in adults; B12 deficiency causes subacute combined degeneration; retics peak at 5-7 days; watch for hypokalemia at start; gastric cancer surveillance in pernicious anemia
MDS - diagnosis
Macrocytic anemia with cytopenias; dysplasia on smear (pseudo-Pelger-Huet, hypogranular neutrophils); hypercellular marrow with dysplasia; cytogenetics del(5q), del(7q); exclude megaloblastic anemia first
MDS - important points
Rich marrow, poor blood (intramedullary apoptosis); age > 50; risk of transformation to AML; caused by benzene, radiation, prior chemotherapy
Anemia of CKD - treatment and important points
Main cause is EPO deficiency; normocytic normochromic; treat with EPO, correct iron and folate, transfuse if symptomatic
Normal hemostasis - important points
Vasoconstriction, primary hemostasis (platelet plug via vWF), secondary hemostasis (fibrin via coagulation cascade), then fibrinolysis by plasmin
PT vs aPTT - important points
PT = extrinsic (factor VII) and common pathway; aPTT = intrinsic (VIII, IX, XI, XII) and common pathway
Vascular bleeding disorders - diagnosis
Mucocutaneous bleeding with NORMAL platelet count and coagulation tests; examples: HHT, scurvy, Henoch-Schonlein purpura, senile and steroid purpura
Thrombocytopenia - important points
ITP - diagnosis
Diagnosis of exclusion; isolated thrombocytopenia with large platelets on smear; exclude secondary causes (ANA, antiphospholipid antibodies, HCV, HIV, H. pylori); marrow only if atypical or refractory (normal/increased megakaryocytes)
ITP - treatment
Corticosteroids 1 mg/kg/day; IVIG for rapid rise; TPO agonists (romiplostim, eltrombopag); splenectomy if other treatments fail
ITP - important points
IgG autoantibodies against platelet glycoproteins; children: acute, post-infection, 90% spontaneous remission; adults: insidious, chronic, F:M 3:1; Evans syndrome = ITP + AIHA
TTP - important points
ADAMTS13 deficiency leads to ultra-large vWF multimers and microthrombi; pentad features: thrombocytopenia, hemolysis, brain ischemia, fever, renal involvement; plasma exchange is the primary treatment
Thrombasthenia - diagnosis and important points
Normal platelet count with abnormal PFA-100; light transmission aggregometry and flow cytometry; Glanzmann = GP IIb/IIIa defect; Bernard-Soulier = GP Ib/IX/V defect and large platelets; aspirin and NSAIDs are the commonest cause
von Willebrand disease - diagnosis
Normal platelet count, abnormal PFA-100, aPTT normal or prolonged; VWF antigen, VWF activity (ristocetin cofactor), and FVIII binding
von Willebrand disease - treatment and important points
DDAVP is effective in type 1; most common inherited bleeding disorder (autosomal dominant); type 1 mild-moderate deficiency, type 2 defective function, type 3 near absent; mucocutaneous bleeding
Hemophilia A - diagnosis
Prolonged aPTT, normal PT, normal platelet count, low factor VIII assay (severity: mild > 5%, moderate 1-5%, severe < 1%)
Hemophilia A - treatment
Recombinant factor VIII concentrate (prophylaxis is superior to on-demand); DDAVP for mild disease; tranexamic acid; FFP or cryoprecipitate if concentrate is not available
Hemophilia B - important points
Factor IX deficiency; treated with factor IX concentrate; DDAVP not effective; cryoprecipitate cannot be used (no factor IX)
Hemophilia vs VWD - important points
Hemophilia: X-linked, hemarthrosis, normal platelet function, prolonged aPTT, normal vWF; VWD: autosomal dominant, mucocutaneous bleeding, abnormal platelet function, decreased vWF
Factor inhibitors - diagnosis and treatment
Diagnosed by aPTT mixing study (fails to correct); treat with bypassing agents (rFVIIa, aPCC) and immunosuppression
Bleeding patient - important points
Best predictor is a detailed history; skin/mucosal bleeding suggests platelet or vascular problem; deep joint/muscle bleeding suggests coagulation defect; petechiae highly suggest platelet disorder
Coagulation screening - interpretation
Prolonged PT = factor VII, VKA, vitamin K deficiency; prolonged aPTT = VIII, IX, XI, XII, vWD, heparin, lupus anticoagulant; both prolonged = V, X, II, I, DIC, advanced liver disease; normal tests with bleeding = VWD, factor XIII deficiency
VTE - diagnosis
D-dimer (negative has high NPV, positive is nonspecific); venous duplex = gold standard for DVT; CT pulmonary angiography for PE (V/Q scan alternative); CT venography for atypical sites
VTE - treatment
Anticoagulation: LMWH 1 IU/kg SC BID or UFH (monitor aPTT); warfarin (INR 2-3) or DOACs (rivaroxaban, apixaban, dabigatran - preferred); DVT 3 months, PE up to 6 months; rtPA for hypotensive PE
VTE - important points
Virchow's triad: endothelial injury, stasis, hypercoagulability; provoked vs unprovoked; transient factors: surgery, OCP, pregnancy, immobility; persistent: active cancer
Thrombophilia - who to test
Unprovoked VTE before age 45, family history with management impact, unusual-site thrombosis, warfarin-induced skin necrosis, recurrent miscarriage; do NOT test provoked VTE or arterial thrombosis routinely
Thrombophilia - important points
Hereditary: protein C, protein S, antithrombin deficiency, factor V Leiden, prothrombin mutation; acquired: HIT, antiphospholipid syndrome, PNH, MPN; heritable thrombophilia alone is not an indication for anticoagulation
Thrombophilia - special treatment situations
HIT: stop heparin and use argatroban; protein C/S deficiency: DOAC rather than warfarin; antiphospholipid syndrome: warfarin indefinitely (not DOAC)
Anticoagulation duration - important points
Provoked: 3 months (6 if cancer); unprovoked: 3-6 months then consider indefinite low-dose DOAC; recurrent VTE or antiphospholipid syndrome: indefinite
AML - diagnosis
Blasts > 20% in marrow (or myeloblasts in blood); immunophenotyping CD13 and CD33; cytogenetics for prognosis; raised LDH, uric acid; echo before chemotherapy
AML - treatment
Supportive (transfusions, antibiotics, leukapheresis for hyperleukocytosis); induction with cytarabine-based chemotherapy; consolidation with cytarabine cycles or allogeneic SCT in high-risk or relapsed disease
AML - important points
M3 (APL) causes DIC and has t(15;17) PML/RARA; M4 and M5 infiltrate gums and CNS; complications: leukostasis, tumor lysis syndrome; splenomegaly and lymphadenopathy uncommon
ALL - diagnosis
Lymphoblasts > 20% in marrow; CD19/CD20 (B-ALL), CD3/CD2/CD7 (T-ALL); CSF analysis, MRI brain/spine, CT chest, scrotal ultrasound
ALL - treatment
Multiagent chemotherapy plus maintenance for at least 2 years; intrathecal CNS prophylaxis is critical; allogeneic SCT for high-risk adults or relapsed disease
ALL - important points
Most common childhood malignancy; lymphadenopathy, splenomegaly, anterior mediastinal mass (T-ALL); testicular and CNS involvement carry poor prognosis; t(9;22) BCR-ABL1 is a high-risk abnormality
CML - diagnosis
WBC often > 100 with all stages of granulocyte maturation; platelets normal or high; hypercellular marrow with blasts < 5%; BCR-ABL1 t(9;22) by cytogenetics or RT-PCR
CML - treatment
Hydroxyurea for cytoreduction; tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib); allogeneic HCT
CML - important points
Philadelphia chromosome; phases: chronic (< 10% blasts), accelerated (10-19%), blastic (> 20%); 95% diagnosed in chronic phase; splenomegaly
CLL - diagnosis
Sustained monoclonal lymphocytes > 5 x 10^9/L; flow cytometry CD19+, CD20+, CD5+, CD23+ with weak surface Ig; smudge cells; marrow >= 30% lymphocytes; DAT if hemolysis suspected; immunoglobulin levels
CLL - treatment
Watchful waiting if asymptomatic; treat for B symptoms, rapid lymphocyte doubling (< 6 months), progressive lymphadenopathy/splenomegaly, or cytopenias; options: chemo (cyclophosphamide, bendamustine), ibrutinib (BTK inhibitor), rituximab
CLL - important points
Mature B cell malignancy; median age 70; usually asymptomatic; hypogammaglobulinemia causes infections; AIHA in ~10%; small, rubbery, non-tender nodes
Polycythemia vera - diagnosis
Hb > 16.5 (men) or > 16.0 (women) or Hct > 49%/48%; low/normal EPO; JAK2 V617F (> 98%); normal O2 saturation; hypercellular marrow with panmyelosis
Polycythemia vera - treatment
Aspirin 80-100 mg for all; phlebotomy to Hct < 45%; hydroxyurea, ruxolitinib, or ropeginterferon for myelosuppression
Polycythemia vera - important points
Aquagenic pruritus after hot bath; hyperviscosity and thrombosis; splenomegaly in 75%; differentiate from secondary erythrocytosis (hypoxia, EPO-secreting tumors)
Essential thrombocythemia - diagnosis and treatment
Platelets >= 450; marrow with clusters of mature megakaryocytes; JAK2, CALR, or MPL mutations (~80%); exclude reactive causes; treat with aspirin, hydroxyurea first-line, anagrelide second-line
Essential thrombocythemia - important points
Arterial more than venous thrombosis; bleeding when platelets > 1000 (acquired vWD); recurrent miscarriage from placental infarcts
Primary myelofibrosis - diagnosis and treatment
Leucoerythroblastic film with teardrop cells; dry tap; reticulin fibrosis on biopsy; treat with supportive care, ruxolitinib (JAK2 inhibitor), splenectomy/irradiation, allogeneic HSCT
Primary myelofibrosis - important points
Massive splenomegaly in virtually all; fibrosis from cytokines released by megakaryocytes; ~30% JAK2 V617F; 15% transform to acute leukemia
Generalized lymphadenopathy - approach
History (course, B symptoms, exposures, drugs), exam (hard/fixed/matted = malignant; soft/tender/mobile = infectious), CBC and smear, LDH, uric acid, HIV/EBV/CMV, CT, PET-CT; excisional biopsy is the gold standard
Hodgkin lymphoma - diagnosis
Excisional lymph node biopsy showing Reed-Sternberg cells; PET/CT and CT for staging (Ann Arbor); raised ESR and LDH are adverse; marrow biopsy only in stage III-IV, bulky disease, or cytopenia
Hodgkin lymphoma - treatment
Stage I-II: 2 cycles ABVD plus involved-field radiotherapy; stage III-IV: 6 cycles ABVD (+/- brentuximab vedotin anti-CD30); relapse: high-dose chemotherapy and transplant
Hodgkin lymphoma - important points
Bimodal age peaks (20 and > 50); EBV in up to 50%; nodular sclerosis most common (60-80%); lymphocyte-depleted has the worst prognosis; rubbery painless nodes; B symptoms and pruritus
NHL - diagnosis
Excisional biopsy (FNA unreliable); immunophenotyping, cytogenetics; labs: LDH, uric acid, beta-2 microglobulin, immunoglobulins, HIV, hepatitis B; imaging: CT and PET; marrow for staging
NHL - treatment
Depends on stage, grade, and phenotype; CHOP or CVP chemotherapy; add rituximab (anti-CD20) for B-cell lymphomas; low-grade asymptomatic = watch and wait
NHL - important points
85% B-cell; indolent (follicular, SLL/CLL), aggressive (DLBCL), highly aggressive (Burkitt); t(14;18) follicular, t(8;14) Burkitt, t(11;14) mantle cell; H. pylori and gastric lymphoma; tumor lysis risk; check hepatitis B before rituximab
Multiple myeloma - diagnosis
Marrow plasma cells >= 10% plus a myeloma-defining event (CRAB or marrow plasma cells >= 60%, FLC ratio >= 100, > 1 focal MRI lesion); SPEP/UPEP, immunofixation, free light chains; skeletal survey, MRI, or PET/CT
Multiple myeloma - treatment
Supportive: hydration, bisphosphonates/denosumab, treat hypercalcemia, plasmapheresis for hyperviscosity; induction with bortezomib + lenalidomide + steroids; autologous SCT for eligible patients; lenalidomide maintenance
Multiple myeloma - important points
Bone pain most common symptom; ESR often > 100; rouleaux and M protein; renal failure from cast nephropathy; recurrent pneumococcal infections; solitary plasmacytoma treated with radiotherapy
MGUS vs smoldering vs myeloma - important points
MGUS: M-protein < 3 g/dL and marrow plasma cells < 10%, most common, observe; smoldering: > 3 g/dL or 10-60% plasma cells without CRAB, monitor; active myeloma: myeloma-defining event, treat
Transfusion indications - important points
RBC: acute loss, Hb < 7 (target >= 9 in elderly/cardiac); FFP: factor deficiency, warfarin overdose, liver disease, DIC, TTP; platelets: < 10 x 10^3, bleeding with low platelets, thrombasthenia
Acute hemolytic transfusion reaction - management
ABO incompatibility; stop transfusion immediately, send unit to blood bank for recross-matching; evidence: increased bilirubin, positive direct Coombs, hemoglobinuria
Febrile non-hemolytic reaction - important points
Most common reaction; cytokines from stored WBCs; diagnosis of exclusion; treat with antipyretics